Povidone-iodine prevents growth of endophthalmitis bacterial isolates after cataract surgery

Article

Administering 5% povidone-iodine for 15 minutes or 10% povidone-iodine for 5 minuytes can contribute towards the prevention of the growth of endophthalmitis bacterial isolates.

Administering 5% povidone-iodine for 15 minutes or 10% povidone-iodine for 5 minutes can contribute towards the prevention of the growth of endophthalmitis bacterial isolates, asserts a study in the Journal of Cataract and Refractive Surgery.

Dr Hamid Hosseini et al., Poostchi Ophthalmology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran, performed an experimental study on 44 patients with postoperative endophthalmitis. Ocular-fluid samples were taken from all patients and evaluated by a microbiology laboratory. One millilitre of 1%, 2%, 5%, and 10% povidone-iodine solutions was combined with one millilitre of microbial isolate suspension. Each solution was transferred to appropriate culture media after 1 minute, 5 minutes and 15 minutes of exposure at 37°C.

Of the patients included in the study, organisms were isolated in 30. In 14 patients coagulase-negative Staphylococcus was identified, Streptococcus species in 8 patients, Staphylococcus aureus in 5 patients, Bacillus cereus in 2 patients and Pseudomonas aeruginosa in 1 patient.

The most effective concentration of solution was 5% povidone-iodine for 15 minutes and 10% povidone-iodine for 5 minutes. After long exposure with 10% povidone-iodine 13% of bacterial isolates remained.

The study advises the use of high concentrations of povidone-iodine with a long exposure time for the isolation of endophthalmitis bacteria post-cataract surgery.

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.